Evofem Biosciences Files 8-K: Agreement Termination & Shareholder Vote

TL;DR

Evofem terminated a major deal and is calling for a shareholder vote. Big changes ahead.

AI Summary

Evofem Biosciences, Inc. filed an 8-K on October 20, 2025, reporting the termination of a material definitive agreement and the submission of matters to a vote of security holders. The filing also includes Regulation FD disclosures and financial statements/exhibits.

Why It Matters

This filing indicates significant corporate actions, including the end of a key agreement and potential shareholder decisions, which could impact the company's future operations and strategy.

Risk Assessment

Risk Level: medium — The termination of a material definitive agreement and a shareholder vote suggest potential instability or significant strategic shifts within the company.

Key Players & Entities

• Evofem Biosciences, Inc. (company) — Registrant
• October 20, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 001-36754 (commission_file_number) — SEC File Number

FAQ

Filing Documents

• form8-k.htm (8-K) — 59KB
• ex99-1.htm (EX-99.1) — 18KB
• ex99-1_001.jpg (GRAPHIC) — 24KB
• 0001493152-25-018687.txt ( ) — 277KB
• evfm-20251020.xsd (EX-101.SCH) — 3KB
• evfm-20251020_lab.xml (EX-101.LAB) — 33KB
• evfm-20251020_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

02. Termination of a Material Definitive

Item 1.02. Termination of a Material Definitive Agreement. As previously disclosed on July 18, 2024 in that Current Report on Form 8-K the Company filed by with the Securities and Exchange Commission ("SEC"), on July 12, 2024 the Company, Aditxt, Inc., a Delaware Corporation ("Aditxt") and Adifem, Inc., a Delaware corporation and wholly-owned subsidiary of Aditxt (the "Merger Sub"), entered into the Amended and Restated Agreement and Plan of Merger (as amended August 20, 2024, September 6, 2024, October 2, 2024, November 19, 2024, March 22, 2025 and August 26, 2025, collectively the "Merger Agreement"), whereby the Merger Sub will merge with and into the Company with the Company being the surviving company and wholly-owned subsidiary of Aditxt (the "Merger"). On October 20, 2025, after the Company's stockholders did not approve a proposal to approve the transactions contemplated by the Merger Agreement. The Company delivered a notice of termination to Aditxt notifying it that the Company was exercising its right to terminate the Merger Agreement effective October 20, 2025 in accordance with Section 8.1(b)(ii), which allows either party to terminate the Merger Agreement if the Merger shall not have been consummated on or before 5:00 p.m. Eastern Time, on September 30, 2025 and as per Section 8.1(b)(iv), which allows either party to terminated the Merger Agreement if the Company Shareholder Approval shall not have been obtained at a duly held Company Shareholders Meeting at which a vote on the approval of the Agreement and the Transactions, including the Merger, was taken. As a result of the termination of the Merger Agreement, all other ancillary agreements related to the Merger Agreement, with the exception of the obligations under the Non-Disclosure Agreement, entered into by and between the Company and Aditxt, as of October 23, 2023, terminated concurrently with the termination of the Merger Agreement. No consideration was paid in connection with the terminati

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. The Company's Special Meeting of the Stockholders (the "Special Meeting") was held on October 20, 2025 at 9:00 a.m. Pacific Daylight Time at the offices of the Company's outside counsel, Procopio, Cory, Hargreaves & Savitch LLP, at 12544 High Bluff Drive, Suite 400, San Diego, California 92130 pursuant to a definitive notice and proxy statement filed with the SEC on September 8, 2025 and additional definitive proxy materials filed with the SEC on September 9, 2025 and September 19, 2025 (collectively, the "Definitive Proxy"). Of the Company's 256,360,511 eligible votes as of August 26, 2025 (the "Record Date"), 100,494,436 votes (approximately 39.2% of the total eligible votes) were represented by proxy or in person, which constituted a quorum for the purposes of the Special Meeting. Approximately 18.5% of eligible votes, present in person or represented by proxy, were from holders of the Company's Common Stock. Approximately 66.7% of the Company's shares of Series E-1 Convertible Preferred Stock issued and outstanding (and eligible to vote on an as-converted basis) as of the Record Date were present in person or represented by proxy. Approximately 53.7% of votes were from holders of the Company's shares of Series G-1 Convertible Preferred Stock issued and outstanding (and eligible to vote on an as-converted basis) as of the Record Date were present in person or represented by proxy. Each of the matters set forth below is described in detail in the Company's Definitive Proxy. The following is a summary of the proposals voted on at the Annual Meeting, including the number of votes cast for, against, and the number of votes withheld and broker non-votes, with respect to each proposal. Proposal 1 To consider and vote upon a proposal to approve the transactions contemplated under the Amended and Restated Merger Agreement dated as of July 12, 2024, as amended (the "Merger Agreement"), with Aditxt,

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical facts contained in this Current Report on Form 8-K are forward-looking statements. In some cases, you can identify forward-looking "indicates," "remains," "believes," "estimates," "forecast," "guidance," "outlook," "may," "will," "should," "seeks," "goals," "targets" or the negative of these terms or other similar expressions. Additionally, forward-looking statements include statements that do not relate solely to historical facts, such as statements which identify uncertainties or trends, discuss the possible future effects of current known trends or uncertainties, or which indicate that the future effects of known trends or uncertainties cannot be predicted, guaranteed, or assured. Forward-looking statements involve risks, uncertainties and assumptions, and are based on information currently available to us. Actual results may differ materially from those expressed in the forward-looking statements due to many factors, including, without limitation, the potential impacts on the Company's business, results of operations and financial condition as a result of the termination of the Merger Agreement and Merger or any challenges to such termination, litigation that may arise from or in connection to the now-terminated Merger Agreement, the risk that any announcements relating to the terminated Merger could have adverse effects on the market price of the Company's common shares, the Company's anticipated sales growth, the Company's ability to successfully execute its growth strat

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: October 20, 2025 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR